SI-BONE Q3 revenue rises 14.5%, slightly beats estimates
SIBN•SI-BONE reported Q3 revenue of $55.70 million, up 14.5% and slightly above the $55.40 million estimate. Net loss narrowed to $3.62 million, and the company reaffirmed 2026 revenue and gross margin guidance while lowering its operating expense growth outlook.
1. Quarterly results
SI-BONE reported Q3 revenue of $55.70 million, up 14.5% and slightly above the $55.40 million consensus estimate. Net loss was $3.62 million, gross margin was 79.3%, and adjusted EBITDA was positive at $3.0 million.
2. 2026 outlook
The company reaffirmed 2026 revenue guidance of $231 million to $233 million and gross margin guidance of approximately 79%. It lowered its expected operating expense growth to 10.5% at the revenue midpoint.
3. Growth drivers
U.S. revenue growth was driven by an approximately 19.5% increase in procedure volume, partly offset by lower average selling prices due to procedure mix and increased demand for the INTRA platform in office-based and ASC sites. Active U.S. physicians grew about 16%; the company also cited early uptake of iFuse Granite Onyx and higher hospital payments for procedures using iFuse Bedrock Granite.
